Immuno-Oncology: Sneak Peek Of Preclinical Candidates Waiting In The Wings

Which immuno-oncology candidates are poised to begin their first-in-human clinical trials? How many sponsors already have partners or collaborators? What oncology indications have been proposed? And where will these trials take place? Citeline's Rachel L. Meighan-Mantha has the data.

Ticket

Plenty of excitement has been generated recently in the immuno-oncology sphere by the accelerated [Food & Drug Administration] approvals in May 2016 for Bristol-Myers Squibb Co.’s PD-1 antagonist, Opdivo (nivolumab), in relapsed/refractory classical Hodgkin’s lymphoma and for Genentech Inc.’s PD-L1 antagonist, Tecentriq (atezolizumab), in relapsed/refractory, advanced or metastatic urothelial carcinoma. Those approvals, along with an abundance of data reported at the ASCO 2016 annual meeting on immuno-oncology (a query of the ASCO 2016 annual meeting abstracts using the keywords related to immune-oncology resulted in almost 1500 abstracts), seems to have spurred multiple investment deals in June and already in July, according to Strategic Transactions.

But which immuno-oncology candidates are poised to begin their first-in-human (FIH) clinical trials? How many sponsors already have partners or...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from R&D

  • ProGen’s Dual Agonist Obesity Contender Gains Momentum With Rani Partnership

     
    • By 

    The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

More from Scrip